Page last updated: 2024-12-08

carbocysteine-lysine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID134128
CHEBI ID135304
MeSH IDM0107349

Synonyms (9)

Synonym
l-lysine, n2-(s-(carboxymethyl)-l-cysteinyl)-
s-carboxymethylcysteine-lys
carbocysteine-lysine
CHEBI:135304
82951-55-1
(2s)-6-amino-2-[[(2r)-2-amino-3-(carboxymethylsulfanyl)propanoyl]amino]hexanoic acid
n2-[s-(carboxymethyl)-l-cysteinyl]-l-lysine trifluoroacetic acid salt
n~2~-{2-amino-3-[(carboxymethyl)sulfanyl]-1-hydroxypropylidene}lysine
DTXSID901003022

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A mass fragmentographic technique was used to study the pharmacokinetic behavior of SCMC-Lys in patients with acute exacerbations of chronic bronchitis and with dense expectoration."( Pharmacokinetic behavior of S-carboxymethylcysteine-Lys in patients with chronic bronchitis.
Allegra, L; Borsa, M; Bossi, R; Braga, PC; De Angelis, L; Scaglione, F; Scarpazza, G, 1982
)
0.26

Dosage Studied

ExcerptRelevanceReference
"7 g once daily, intermittent SCMC-Lys at the same dosage (1-week courses alternating with 1-week intervals on placebo) or placebo."( Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial.
Allegra, L; Cordaro, CI; Grassi, C, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's5 (31.25)18.2507
2000's5 (31.25)29.6817
2010's2 (12.50)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.71 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index47.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (26.32%)5.53%
Reviews2 (10.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational2 (10.53%)0.25%
Other10 (52.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]